Evidence map›Paper›PMID 32556804›Full record

ArticleMolecular diversity2021

Head-to-head bisbenzazole derivatives as antiproliferative agents: design, synthesis, in vitro activity, and SAR analysis.

Ronak Haj Ersan, Mehmet Abdullah Alagoz, Tugba Ertan-Bolelli, Nizami Duran, Serdar Burmaoglu, Oztekin Algul

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular diversity, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. New chalcone derivatives as effective against SARS-CoV-2 agent.International journal of clinical practice · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 1 country.

Ronak Haj ErsanDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Mersin University, 33169, Mersin, Turkey.
Mehmet Abdullah AlagozDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Inonu University, 44280, Malatya, Turkey.
Tugba Ertan-BolelliDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Ankara University, 06560, Ankara, Turkey.
Nizami DuranDepartment of Medical Microbiology, Medical Faculty, Mustafa Kemal University, 31100, Antakya, Hatay, Turkey.
Serdar BurmaogluDepartment of Chemistry, Faculty of Science, Ataturk University, 25240, Erzurum, Turkey. serdarburmaoglu@atauni.edu.tr.ORCID http://orcid.org/0000-0001-8288-7423
Oztekin AlgulDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Mersin University, 33169, Mersin, Turkey. oztekinalgul@mersin.edu.tr.ORCID http://orcid.org/0000-0001-5685-7511
Mersin Üniversitesi · TRAnkara University · TRAtatürk University · TRInonu University · TRMustafa Kemal University · TR

Funding

Mersin Üniversitesi 2018-1-TP3-2911Türkiye Bilimsel ve Teknolojik Araştirma Kurumu 115S190
6 · The paper itself

Abstract

In the present work, a series of bisbenzazole derivatives were designed and synthesized as antiproliferative agents. The antiproliferative activity of these compounds was investigated using MTT assay. Bisbenzazole derivatives showed significant antiproliferative activity against all the four tested cancer cell lines. Among the various bisbenzazole derivatives, bisbenzoxazole derivatives exhibited the most promising anticancer activity followed by bisbenzimidazole and bisbenzothiazole derivatives. All the derivatives were found to be less toxic as compared to methotrexate (positive control) in normal human cells, indicating selective and efficient antiproliferative activity of these bisbenzazole derivatives. The structure-activity relationships of heteroaromatic systems and linkers present in bisbenzazole derivatives were analyzed in detail. In silico ADMET prediction revealed that bisbenzazole is a drug-like small molecule with a favorable safety profile. Compound 31 is a potential antiproliferative hit compound that exhibits unique cytotoxic activity distinct from methotrexate. Twenty-one bisbenzoxazole derivatives have been designed synthesized and evaluated to be an antiproliferative activity against four human tumor cell lines.

Indexed as

Antineoplastic AgentsCell ProliferationDrug DesignDrug Screening Assays, AntitumorBenzimidazolesBenzoxazolesCell Line, TumorHumansStructure-Activity RelationshipAntineoplastic AgentsBenzimidazolesBenzoxazolesADMETAntiproliferative activityBisbenzimidazoleBisbenzothiazoleBisbenzoxazoleSAR

Identifiers

PMID32556804
OpenAlexW3036957334

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.